2 Results for "

DNA-compatible

" in MedChemExpress (MCE) Product Catalog:
Products (2)

2 Results for "DNA-compatible" in MCE Product Catalog:

Cat. No.: HY-42045
CAS No.: 321724-19-0
Pyrimidine-5-boronic acid pinacol ester is a derivative of Boronic acid. Boronic acid is an intermediate commonly used in organic synthesis reactions and can be used as a key reagent in the Suzuki-Miyaura reaction. It generates organic free radicals through oxygen-mediated oxidation and exhibits potential mutagenic activity. Boronic acid is mainly used in research in the fields of drug synthesis and catalytic reactions. Pyrimidine-5-boronic acid pinacol ester serves as a building block in DNA-compatible one-pot click chemistry for synthesis of DNA-encoded libraries .
loading...
    loading...
Cat. No.: HY-LD005
1.2 billion compounds

Cyclic peptide library have advantages such as high affinity, high selectivity, and suitability for targeting protein–protein interactions. Through DEL synthesis technology, the library size can achieve hundreds of millions. DEL cyclic peptide library have advantages like low cost andhigh screeing efficiency, making them valuable for discovering lead compounds against challenging drug targets.

This cyclic peptide library is constructed with unnatural amino acids as building block, synthesized through DNA-compatible chemical reactions. Each cyclic peptide consist of six amino acids and constrained conformations such as side-chain cross-linking, disulfide bonds, and macrocyclization. These cyclic peptides exhibit significantly improved stability and druggability compared with linear peptides, filling the gap between small molecules and macromolecular biologics. Each cyclic peptide is uniquely conjugated to a DNA barcode sequence for molecular identification and sequencing decoding.

MCE’s cyclic peptide library has8 independent sub-libraries, with a total molecular diversity of 1.2 billion. It is constructed via multi-round combinatorial assembly of building blocks and diverse cyclization strategies, facilitating the discovery of cyclic peptide leads for undruggable targets.